Skip to main content Help with accessibility Skip to main navigation

Finerenone

Indication

Chronic kidney disease in type 2 diabetes - NICE TA877

NICE TA 877 - Finerenone for treating chronic kidney disease in type 2 diabetes

Green

Brand:

kerendia

Nice TA:

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Endocrine system

Background

1.1 Finerenone is recommended as an option for treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. It is recommended only if:

• it is an add-on to optimised standard care; this should include, unless they are unsuitable, the highest tolerated licensed doses of:

- angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) and

- sodium–glucose cotransporter-2 (SGLT2) inhibitors and

• the person has an estimated glomerular filtration rate (eGFR) of 25 ml/min/ 1.73 m 2 or more.

Recommendation

LSCMMG Recommendation:

Green

Reason for decision:

Suitable for initiation in primary care

Supporting documents:

Decisions of Lancashire local decision making groups

Pending
Pending
Pending
Pending
Pending
Pending
Pending
Pending
What do the colours mean?

Last Updated: 27 - Apr - 2023